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(ADP-ribose) glycohydrolase (PARG) enzymes and the 
amino acid sequences of PARGs from several species are 
described. PARG is involved in the cellular response to 
DNA damage and its proper function is associated With the 
body’s response to neoplastic disorder inducing agents and 
oxidative stress. Expression vectors containing the cDNAs 
and cells transformed With the vectors are described. Probes 
and primers that hybridize With the cDNAs are described. 
Expression of the cDNA in E. coli results in an enzymati 
cally active protein of about 111 kDa and an active fragment 
of about 59 kDa. Methods for inhibiting PARG expression 
or overexpressing PARG in a subject for therapeutic bene?t 
are described. Exemplary of PARG inhibitors are anti-sense 
oligonucleotides. The invention has implications for treat 
ment of neoplastic disorder, heart attack, stroke, and neu 
rodegenerative diseases. Methods for detecting a mutant 
PARG allele are also described. Antibodies immunoreactive 
With PARGs and fragments thereof are described. 
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GENES ENCODING SEVERAL POLY(ADP 
RIBOSE) GLYCOHYDROLASE (PARG) 
ENZYMES, THE PROTEINS AND 
FRAGMENTS THEREOF, AND ANTIBODIES 
IMMUNOREACTIVE THEREWITH 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application is a divisional of US. application Ser. 
No. 09/302,812 ?led Apr. 30, 1999, Which claims bene?ts of 
US. provisional Application No. 60/083,768 ?led May 1, 
1998. The entire disclosure of US. application Ser. No. 
09/302,812 and US. Provisional Application No. 60/083, 
768 is incorporated herein by reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
The present invention Was supported in part by the 
National Institutes of Health (Grant CA43894). The United 
States Government may have certain rights in the invention. 
TECHNICAL FIELD 
The present invention relates to poly(ADP-ribose) glyco 
hydrolases (PARGs) and peptides having poly(ADP-ribose) 
glycohydrolase activity. In addition, the invention also 
relates to antibodies, including monoclonal antibodies and 
antibody fragments, that have speci?c interaction With 
epitopes present on poly(ADP-ribose) glycohydrolases. 
Methods of treatment and diagnosis using the poly(ADP 
ribose) glycohydrolases, and antibodies speci?c for poly 
(ADP-ribose) glycohydrolases are disclosed. The present 
invention has implications for the treatment of neoplastic 
disorder, reperfusion folloWing ischemia, neurological 
disorders, and related conditions. 
BACKGROUND OF THE INVENTION 
Genomic damage, if left unrepaired, can lead to malignant 
transformation, or cell death by senescence (aging), necrosis 
or apoptosis. Among the variables that can affect the ulti 
mate biological consequence of DNA damage to a particular 
cell are the amount, type, and location of the DNA 
damage and (ii) the ef?ciency and bioavailability of the 
cellular DNA repair mechanism. 
The activation of poly(ADP-ribose) polymerase (PARP) 
by DNA strand breaks is often one of the ?rst cellular 
responses to DNA damage. PARP catalyZes the conversion 
of nicotinamide adenine dinucleotide (NAD) to multi 
branched polymers containing up to 200 ADP-ribose resi 
dues. Increases in polymer levels of more than 100-fold may 
occur Within minutes of DNA damage. Once synthesiZed, 
polymers are rapidly turned over, being converted to free 
ADP-ribose by the action of poly(ADP-ribose) glycohydro 
lase (PARG) An ADP-ribosyl protein lyase has been 
proposed to catalyZe removal of protein-proximal ADP 
ribose monomers FIG. 1 illustrates these processes 
schematically. 
The process of activating PARP upon DNA damage can 
rapidly lead to energy depletion because each ADP-ribose 
unit transferred by PARP consumes one molecule of NAD, 
Which in turn, requires siX molecules of ATP to regenerate 
NAD. Additionally, NAD is a key carrier of electrons needed 
to generate ATP via electron transport and oXidative phos 
phorylation or by glycolysis. The overactivation of PARP 
due to substantial DNA damage can signi?cantly deplete the 
cellular pools of NAD and ATP ADP-ribose polymer 
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metabolism, and thus PARP and PARG have been linked to 
the enhancement of DNA repair (4), limitation of malignant 
transformation (5), enhancement of necrotic cell death (6), 
and involvement in programmed cell death To date, 
studies of the structure and function of the enZymes of 
ADP-ribose polymer metabolism have been mainly limited 
to PARP Little is knoWn about the function and regu 
lation of PARG. 
BRIEF SUMMARY OF THE INVENTION 
As embodied and broadly described herein, the present 
invention is directed to nucleic acids molecules, peptides, 
methods, vectors and antibodies that are related to the 
poly(ADP-ribose) glycohydrolase (PARG) enZyme. 
One embodiment of the invention is directed to an iso 
lated and puri?ed nucleic acid molecule or nucleic acid 
molecule analog comprising a sequence that encodes a 
polypeptide having poly(ADP-ribose) glycohydrolase 
(PARG) activity. The nucleic acid molecule may encode the 
complete full-length PARG gene or a fragment of the PARG 
gene. The nucleic acid molecule may be DNA, RNA or 
peptide nucleic acid (PNA). The nucleic acid molecule can 
be linear, such as, for eXample, an isolated fragment or a 
linear phage DNA. In addition, the isolated nucleic acid 
molecule may be circular, such as for eXample in a plasmid. 
The nucleic acid molecule may also be a single stranded 
DNA or RNA such as the single stranded DNA or RNA in 
a single stranded DNA virus or single stranded RNA virus. 
The nucleic acid molecule may be of yeast, insect or 
mammalian origin. 
The nucleic acid molecule of the invention, may be of 
mammalian origin, such as, for eXample of bovine or murine 
origin. In a preferred embodiment of the invention, the 
nucleic acid molecule may be of human origin. While the 
sequence of the nucleic acid molecule is of mammalian 
origin, the nucleic acid molecule may be replicated in 
another organism such as an insert in a viral genome, a 
plasmid in a bacterium or a 2-micron plasmid in a yeast. 
Preferably, the nucleic acid molecule has, a high degree of 
sequence similarity With a sequence shoWn in SEQ ID NO: 
1 (Genbank Accession Number U78975), SEQ ID NO: 3 
(Genbank Accession Number AF005043), SEQ ID NO: 5 
(Genbank Accession Number AF079557), SEQ ID NO: 7 
(Genbank Accession Number AF079556) or SEQ ID NO: 9 
(Genbank Accession Number CEF20C5). The high degree 
of sequence similarity may be, for example, about 70%, 
preferably about 80%, even more preferably about 90% and 
most preferably substantially identical such as for eXample 
about 100% identity. 
The nucleic acid molecule that encodes a polypeptide 
having poly(ADP-ribose) glycohydrolase (PARG) activity 
may be single or double stranded nucleic acid molecule of 
any length such as, for eXample, about 20 bases in length, 
about 30 bases in length, about 40 bases in length, about 50 
bases in length, about 100 bases in length, about 200 bases 
in length, about 500 bases in length, about 1000 bases in 
length, about 1500 bases in length, about 2000 bases in 
length, about 3000 bases in length. It is understood that 
“bases” in this patent application means “basepairs” When 
referring to double stranded nucleic acid molecules and 
bases When referring to single stranded nucleic acid mol 
ecules. In a preferred embodiment of the invention, the 
nucleic acid molecule may be at least about 1000 base or 
basepairs long and have at least about 80% sequence simi 
larity With a sequence shoWn in SEQ ID NO: 1, SEQ ID NO: 
3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9. 

























































